Composition for treating skin pigmentation

Inactive Publication Date: 2013-06-27
LONZA WALKERSVILLE INC
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is a topical composition that can help speed up the breakdown of bilirubin in the skin. It contains an extract from certain plants, a preservative, and a dermatologically-friendly carrier. The composition can be made into a concentrated form that has a certain amount of Non-Volatile Matter. The method for using the composition involves applying it to the skin. This invention can help reduce the buildup of untilin in the skin, which can cause skin issues like yellowing or erythema.

Problems solved by technology

When these molecules accumulate near the surface of the skin, they can manifest themselves as undesirable spots such as bruises, dark circles, and other skin pigment disorders.
This includes principally blood vessel leakage, accumulation of blood and blood degradation by-products around the eyes, and ineffective drainage of the blood and blood by-products through the lymph system surrounding the eyes.
Similar problems can occur in skin that is damaged by bruising usually from some form of blunt force trauma which causes the blood vessels in the skin to leak but does not result in breakage of the skin to provide external bleeding relief.
While these products can be helpful, they have to be carefully blended with the surrounding skin color, which changes throughout the day, and so are only a partial solution to the problem.
Understandingly, the use of harsh chemicals for treatments around the eyes is not welcomed by many consumers as the eye is sensitive to stinging and irritating chemicals.
What all of these prior inventions fail to disclose are methods to actually accelerate the degradation of the heme by-products as a means to control under eye color.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating skin pigmentation

Examples

Experimental program
Comparison scheme
Effect test

example 1

Extraction of Arils of Strelitzia nicolai (Extract Concentrate)

[0039]A 1% aril solution was created by homogenizing 3 g of Strelitzia nicolai in 297 mL, pH 7.0 water in an ice bath using a Silverson L4R homogenizer (Chesham Bucks, England) at a speed of 4000 rpm for 10 minutes. The solution was further homogenized using a Niro Panda 2K (Bedford, N.H., USA) by passing the solution four times through the Niro homogenizer at 1000 bar pressure. After homogenization, the pH was brought up to 7.0 using a 0.1% NaOH solution.

[0040]The homogenized solution was filtered sequentially through four Whatman filters: #41, #2, #6, and #5, respectively, which correspond to 25 μm, 8 μm, 3 μm, and 2.5 μm. Finally, the solution was filtered through a 0.2 μm Nalgene filter. The solution was then concentrated to remove water in order to achieve a final NVM of Strelitzia nicolai aril extract concentrate having approximately 13% extract concentrate solids.

example 2

Bilirubin Degrading Ability of Strelitzia nicolai Aril Extract

[0041]For high pressure liquid chromatography (HPLC) analysis, a control of 0.050% bilirubin (Frontier Scientific, Logan, Utah) in pH 7.0 water was run along with samples of the Strelitzia nicolai aril extract concentrate of Example 1. The aril extract was diluted with pH 7.0 water to give a final concentration of 0.1%, 0.5% or 0.95% Strelitzia nicolai aril extract along with a 0.050% concentration of bilirubin in each solution.

[0042]HPLC solutions were prepared as described in Spivak and Yuey, Biochem. J. (1986) 234 (101-109), which is incorporated by reference herein. For HPLC solvent A, 0.04 M sodium acetate in methanol was prepared by dissolving 3.282 g sodium acetate from Sigma Chemical Co (St. Louis, Mo., USA) in 1000 mL methanol from Fisher Scientific (Pittsburgh, Pa., USA). For solvent B, 1% ammonium acetate in water was prepared by adding 10 ml of glacial acetic acid from Fisher Scientific to 990 ml of distilled ...

example 3

Preparation of Strelitzia nicolai Aril Extract in Oil-in-Water Emulsions

[0046]The Strelitzia nicolai aril extract from Example 1 was formulated into an oil-in-water emulsion using the following formulation and process:

IngredientINCI Nomenclature%Phase (A)WaterWaterQ.s to 100Versene ™ 100Tetrasodium EDTA0.10GlycerinGlycerin2.00Carbopol ® Ultrez 10Carbomer0.20Phase (B)Brookswax ™ DCetearyl Alcohol and Ceteareth-202.00Liquiwax DIADD**DioctyldodecylDodecanedioate5.00Loronate TMP-TCTrimethylolpropaneTricaprylate / 2.00TricaprateArlacel ™ 60Sorbitan Stearate1.50Stearyl AlcoholStearyl alcohol0.20Cetyl AlcoholCetyl Alcohol0.50Stearic AcidStearic Acid0.50Myritol ® 318Caprylic / Capric Triglyceride2.00DC 200 / 100 cSTDimethicone0.75Phase (C)WaterWater5.00TEA 99Triethanolamine0.25Phase (D)Extract Example 1—1.00Mikrokill ® COSPhenoxyethanol, Caprylyl Glycol,0.75and ChlorphenesinProcedure:1. Combine Phase A and heat to 75° C. Mix until uniform.2. Combine Phase B and heat to 75° C. Mix until uniform.3....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a topical composition containing a bilirubin-producing plant extract. In particular, the bilirubin-producing plant extract is obtained from the genus Strelitzia. When topically applied to skin, the composition is effective in accelerating the degradation of heme by-products such as bilirubin present in the skin.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Application No. 61 / 579,178 filed Dec. 22, 2011, which is herein incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to compositions effective in accelerating the degradation of heme by-product accumulation in the skin, particularly bilirubin accumulated in bruised skin or areas under the eyes. More particularly, the present invention relates to topical compositions containing an extract derived from the plants of the genus Strelitzia or Phenakospermum, and to the manufacture and methods of using such compositions.BACKGROUND OF INVENTION[0003]The human body comprises a number of pigmented molecules that contain porphyrin-containing components that comprise iron as part of the porphyrin molecule. These are frequently referred to as “heme” type molecules. Hemoglobin, and to a lesser extent, myoglobin, neuroglobin and cytoglobin are well-known porphyrin-c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K8/97G01N33/72C12Q1/25A61Q19/02
CPCA61K8/97A61Q19/02Y10T436/146666G01N33/728C12Q1/25A61K8/9794A61P3/00A61P17/00A61P17/16Y10T436/145555A61K2800/40G01N2500/04G01N2500/20G01N33/50
Inventor GRUBER, JAMES V.LUDWIG, PHILIP L.
Owner LONZA WALKERSVILLE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap